COL4A4 genes that encode the α3 and α4 chains of type IV collagen, respectively, a major structural protein in the glomerular basement membrane. The aim of this study was to explore a new diseaserelated genetic mutation associated with the clinical phenotype observed in a Chinese Han family with autosomal dominant TBMN. We conducted a clinical and genetic study comprising seven members of this TBMN family. Mutation screening for COL4A3 and COL4A4 was carried out by direct sequencing. The RNA sequences associated with both proteins were also analyzed with reverse transcription PCR and TA cloning. The result showed that every affected patient had a novel heterozygous splicing mutation in COL4A4 (c.1459 + 1G > A), which led to the elimination of the entire exon 21 from the COL4A4 cDNA and resulted in the direct splicing of exons 20 and 22. This in turn caused a frameshift mutation after exon 20 in the open reading frame of COL4A4. In conclusion, we describe a novel splicing mutation in COL4A4 that results in TBMN. This analysis increases our understanding of TBMN phenotype-genotype correlations, which should facilitate more accurate diagnosis and prenatal diagnosis of TBMN.
Thin basement membrane nephropathy (TBMN), also called benign familial hematuria, is the most common cause of inherited persistent microscopic hematuria in children and adults that occurs in at least 1% of the population 1, 2 . It is characterized by persistent hematuria, minimal proteinuria, normal renal function and a uniformly thinned glomerular basement membrane(GBM) 2, 3 . Although renal function of TBMN patients does not progress to chronic renal failure (CRF) or end stage renal disease (ESRD), about 10-20% patients with TBMN will development to ESRD in later life at a mean age of 60 years 4 . Currently, as no clear evidence-based treatment protocols are available for TBMN, early and accurate diagnosis for an individual patient is very important for early effective prevention of ESRD.
Autosomal dominant mutations of COL4A3 or COL4A4 are associated with TBMN 5 . COL4A3 and COL4A4 encode the α 3 and α 4 chains of type IV collagen respectively, which are the major structural components of the GBM. The defects in COL4A3 or COL4A4 may lead to type IV collagen related nephropathies that comprise a spectrum of phenotypes ranging from the severe phenotype Alport syndrome (AS) to its mild variants, TBMN 6 . Since the first COL4A4 mutation in TBMN has been described by Lemmink in 1996 7 , at present, at least twenty one different mutations have been identifiedscattered in most of the coding exons of human COL4A3 or COL4A4 and no mutational "hotspots" were found 8 . Most mutations can result in single nucleotide substitutions which cause missense or nonsense mutations. In addition, six insertion or deletion mutations have been reported 3 . Although many different mutations in COL4A3 and COL4A4 have already been identified, a valid mutational spectrum of these two genes and genotype-phenotype correlation for TBMN or AS is not yet fully known. Therefore, it is essential to identify new mutations in COL4A3 and COL4A4 by direct sequencing to clarify their clinical phenotype and to assess the prognosis for TBMN which can help then understand this disease, and other Type IV collagen related diseases on the basis of the genotype and made further it possible to carry on prenatal diagnosis in affected members.
In this present study, we investigated a pedgree with TBMN from Shandong provience, China and performed mutational analyses in COL4A3 and COL4A4, to add to the existing genotype-phenotype correlations within these genes.
Results
Clinical phenotypeof proband. The proband (II5, Fig. 1 ) presented with continuous microhematuria and microalbuminuria over 6 years. The pleomorphism of the erythrocytes in the urinary sediment indicated the glomerular origin of the cells. The glomerular filtration rate was normal but the urinary osmolality was slightly decreased (676 mOsm/kg). There were no signs of arterial hypertension, hearing loss, or lenticonus or macular flecks. The detailed clinical festures and urine routine test of proband and the carriers (II2 and I2, Fig. 1 ) were shown in Table 1 .
Immunohistochemical renal biopsy of the proband (Fig. 2 A,B) showed almost normal glomerular histology with only occasional mild mesangial cellular proliferation and matrix expansion under light microscopy in Periodic Acid-Schiff staining (PAS). Periodic Acid-Silver Methenamine (PASM)can dye GBM and mesangial matrix black and Masson staining can dye the GBM, mesangial matrix as well as renal interstitium green. The result of PASM and Masson staining indicated no obvious immune complex deposits in kidney (Fig. 2 C,D) . The percentage of focal glomerular sclerosis was approximately 7.3% and interstitial fibrosis was moderate (+ + ). A few erythrocyte casts and protein casts could be identified in the tube, while the interstitial capillaries were normal. Ultrastructural images (Fig. 3) showed characteristically thinned GBM of 144-204 nm, and few podocyte fusions were found. No other structural abnormalities were apparent. There was no mesangial matrix expansion and no dense materials were visible in the mesangial area or in the basement membrane. Immunofluorescence for IgM showed diffuse distribution in mesangial area with weak fluorescence intensity (Fig. 4) . To further distinguish TBMN from early stage AS, immunofluorescence for type IV collagen α 3 and α 5 chains were performed. Immunofluorescence evaluation of the type IV collagen α 3 and α 5 chains in renal biopsy displayed a normal state (Fig.4) . Next we carried on genetic testing directly toidentify the mode of inheritance and the nature of the underlying mutation. were found in COL4A3. This mutation was subsequently screened for across all family members. The same mutation was found only in the eldest sister (II2) and the mother (I2). Direct sequence analysis of 200 normal chromosomes from healthy control subjects of the same ethnic origin did not identify the same mutation. Therefore, this novel splice mutation is most likely the causal mutation responsible forthe TBMN phenotype in this family (Fig. 5 ).
RNA analysis. RNA sequence analysis of the proband confirmed that the c.1459 + G > A splice mutationof COL4A4 eliminated the entire exon 21 from the COL4A4 cDNA, with the result that exon 20 and 22 were directly spliced together ( Fig. 6 ), which further caused a frameshift mutation after exon 20 in the coding sequence ofCOL4A4. We observed this change at the RNA level in all affected family members including II2 and I2, but not in the healthy family members.
Discussion
The GBM is formed by a type IV collagen network. The triple-helical type IV collagen molecules form a network by associating with each other at their ends that forms the structural skeleton of the basement membranes 9 . Up till now, six different type IV collagen chains α 1 to α 6 have been identified, which are encoded by COL4A1 to COL4A6, respectively. With the development of kidney, the α 1α 2 protomer is gradually replaced by the α 3α 4α 5 protomer therefore the α 3:α 4:α 5 chain is a major component of the GBM after birth, which is more cross-linked and resistant to degradation 10 . Co-located on 2q36.3, COL4A3 contains 52 exons and encodes the α 3 chain (1670 amino acids) while COL4A4 contains 48 exons and encodes the α 4 chain (1690 amino acids) 11 . The α 3 and α 4 chains combine with α 5 chains to make a complete type IV collagen molecule, which attachs to each other to form complex protein networks. Possible effects of COLA43 and COL4A4 mutations in TBMN could be a hamper in developmental switch to the α 3α 4α 5 network, a decreased content of type 4 collagen chains, a reduced cross linking in the type IV collagen network and eventually adecreased thickness and stability of the GBM, resulting in TBMN or AS.
The diagnosis of TBMN is made clinically when there is persistent glomerular hematuria, minimal proteinuria (500 mg/d), normal renal function(mostly), and no other obvious extrarenal abnormalities 12 . About 40% families with TBMN have hematuria that segregates with the mutations in COL4A3/COL4A4 locus and about two thirds of individuals with TBMN have at least one other family member with hematuria in autosomal dominant inheritance pattern 13 . Families with TBMN in whose hematuria does not segregate with the COL4A3/COL4A4 locus can be explained by de novo mutations, incomplete penetrance of hematuria, coincidental hematuria in family members without COL4A3 or COL4A4 mutations, or by an as yet unidentified causative gene locus for TBMN 1 . Several typical features of AS include haematuria, proteinuria, progressive renal failure, progressive sensorineural hearing loss(SNHL), anterior lenticonus, positive family history for haematuria, splitting and thickening of the glomerular basement membrane, and renal disease progresses from microscopic hematuria to proteinuria, progressive renal insufficiency and end-stage renal disease (ESRD) 14 . X-linked dominant AS is the major form (85% of the cases) and is associated with mutations in the X-linked COL4A5 15 . 15% of the cases follow autosomal-recessive inheritance (ARAS) which is caused by homozygous or compound heterozygous mutations in COL4A3 and COL4A4 16 . The remaining 5% autosomal-dominant type of AS (ADAS) were due to heterozygous COL4A3 or COL4A4mutation 17 . 
TBMN and AS have morbigenous mutations in the same genes (COL4A3 or COL4A4). Lemmink et al. first suggested patients with TBMN that is linked to chromosome 2 are heterozygous for mutations in either COL4A3
or COL4A4, and they represent a carrier status for ARAS 7 . To date, six mutations have been described that are common to both conditions (G464V, G1015E in COL4A3 and R1377X, S969X, a184-bp deletion in intron 24 and exon 25, and an 18-bp deletion in exon 25 in COL4A4) 5, 18, 19 . These observations confirmed that TBMN represented the carrier state for ARAS at least in some families. So, it posed a challenge to accurately diagnose the two diseases in this condition. Apart from the differences in clinical manifestations, renal biopsy can be a distinction standard. It has been reported that the mean GBM thickness in female adults was found to be 320 ± 50 nm 20 and the World Health Organization (WHO) had proposed a threshold of 250 nm for adults in TBMN. While in AS, renal biopsies are characterized by irregular thickening of the GBM 21 . More precisely distinction may refer to specific disease-causing genes.
To date, about 21 mutations in COL4A3 and COL4A4 have been idenfied in TBMN, and most of these are single nucleotide substitutions that are different in each family. For example, missense mutations (G957R, G960R, S969X in COL4A4 and G464V, G532C, G584C, G596R, G695R, G985V, G1015E in COL4A3) all affect a glycine residue 5, [22] [23] [24] [25] , which is the only amino acid small enough to fit the triple helix structure of the collagen network. The splice site (c.1935 del18) mutation eliminates18-bp in exon 25 in COL4A4, producing a shift in the reading frame that leads to a truncated protein missing half of the collagenous domain 19 . IVS23-1G > C in exon 24 of COL4A4 and IVS40-7 C > G and IVS351 G > A in COL4A3 produce an aberrant splicing to be associated with TBMN 22 . Therefore, the identification of novel mutations in these genes is particularly important to enable diagnostic laboratories to distinguish mutations from uncommon normal variants so as to ascertain the relationship of genotype-phenotype in TBMN and AS.
In this present study, the COL4A4 c1459 + G > A was first reported in the literature as a heterozygous change in a 35-year old female proband with history of microhematuria, mild proteinuria and uniformly thinned GBM (144-204 nm). The proband did not have sensorineural hearing loss or ocular features, and her mother and sister, who was also heterozygous for this mutation, had history significant for microhematuria. The mode of inheritance was therefore suggested to be autosomal dominant. In X-linked AS, the collagen IV α 5 chain, as well as the α 3 and α 4 chains are often absent from the GBM; and in ARAS, the α 3α 4α 5 network is absent from the GBM 26 . Based on the above evidences we excluded X-linked dominant AS and ARAS clinically because the proband lacked the typical characteristics of AS, with normal type IV collagen α 3/α 5 chains and autosomal dominant inheritance pattern. ADAS and TBMN both exhibit normal GBM staining for the collagen α 3(IV) chain and α 5(IV) chain. ESRD and SNHL are relatively late in onset and ocular involvement is rare in ADAS. But in ADAS, the lamina densa appears to be split into multiple interlacing strands of electron-dense material; the lacunae between these strands are frequently occupied by round, electron-dense bodies; the glomerular capillary wall is diffusely thickened 14 . Therefore, we can conclude that the c1459 + G > A mutation can cause the mild phenotype TBMN rather than AS in this China Han family. If the COL4A4 c1459 + G > A also exists in ADAS patients or if it is common to both conditions still remains to be further explored.
Further investigation demonstrated the underlying pathogenic mechanism that this splice site mutation can eliminate exon 21 from the cDNA to further cause frameshift mutation after exon 20 in the open reading frame of COL4A4 and result in changes in amino acid sequence of α 4 chain. As the linear amino acid sequence of a protein is the primary structure of protein and determines its secondary, tertiary and quaternary structure, we may come to a conlusion that the COL4A4 c1459 + G > A mutation generated abnormal α 4 chain of type IV collagen, then influenced the α 3α 4α 5 protomer to form correctly, eventually affect the α 3α 4α 5 network and structural skeleton of the sement membranes, leading to TBMN in this family.
In conclusion, we identified a novel splice pathogenic mutation that is responsible for this TBMN pedigree through aberrant splicing and frameshift mutation. To our knowledge, this is the first report of COL4A4mutation in any population. Our findings also demonstrate genetic heterogeneity of the mutation and add to knowledge of the correlations of phenotype-genotype in TBMN. Such knowledge might assist in understanding the mechanism of the pathophysiology of TBMN, and form the basis of more accurate and rapid diagnosis of this hereditary birth defect.
Materials and Methods
Patients. The subjects were a Chinese family of seven from Shandong province, China. The proband (II5), a 35-year-old woman, under wentrenal biopsy, which revealed uniformly thinned GBM. She subsequently asked for genetic counselling and prenatal diagnosis. Her mother and eldest sister were both diagnosed with having microhematuria for more than 10 years, but were negative for renal failure and hearing loss. Herfather and other three siblings, two males and onefemale, did not show any significant symptoms or abnormalities on testing (Fig. 1) . After written informed consent was obtained, blood samples were collected from all family members. The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University and the methods were carried out in accordancewith the approved guidelines.
Mutation screening. Genomic DNA from all participating family members was extractedfrom the peripheral blood leukocytes using the phenol-chloroform method. All coding exons and splice sites of COL4A3 (NM_000091.4; 52 exons) and COL4A4(NM_000092.4; 48 exons) were PCR-amplified using gene-specific primer pairs designed with Primer5 (Premier Biosoft International, version 5.0). The annealing temperatures used were between 50-60 °C. Amplified PCR products were purified and sequenced using the appropriate PCR primers and the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA), and run on an automatedsequencer, ABI 3730xl (Applied Biosystems), to perform mutational analysis. DNA sequences Scientific RepoRts | 6:20244 | DOI: 10.1038/srep20244
were analyzed using the BioEdit (Borland, V7.0.1) program and compared to a reference sequence from the GenBank database.
RNA analysis and TA cloning. RNA from 1 mL peripheral blood leucocytes was isolated with the QIA amp RNA Blood Mini kit (Qiagen, Hilden, Germany). cDNA was prepared from the total RNA with PrimeScript RT Enzyme Mix using the PrimeScript RT Reagent Kit with RNA Eraser (TaKaRa, Japan) according to the manufacturer's instructions. RNA sequences containing the mutation site was amplified by PCR. The primers used for PCR analysis were 5ʹ -CCTGTGCAGGCATGATAGGA-3ʹ and 5ʹ -TGCCCTTTAACTCTTGATACAACCA -3ʹ . PCR products were separated by 1% agarose gel electrophoresisand target DNA was extracted with a Gene JET Gel Extraction Kit (Thermo Scientific, Waltham, MA, USA). pMD19-T vector(1 μ L; TaKaRa) was mixed and incubated with 4 μ L target COL4A4 DNA at 16 °C for 30 min. This mixture was added to 100 μ L TOP10 competent cells and incubated for 30 min on ice, 1 min at 42 °C, then 2 min on ice as per manufacturer's instructions, toallow the transformation of TOP10 competent cells with the pMD19-T vector containingthe target DNA. Luria Broth (LB) was added to each tube (900 μ L) and the cells were cultured at 37 °C, 150 rpm for 45 min. Then, 100 μ L of the transformed cells were spread evenly on LB-agar plates containing 100 mg/mL penbritin, 24 mg/mL IPTG, and 20 mg/mL X-Gal, and cultured at 37 °C for 16h. Cells transformed with vectors containing recombinant DNA produced white colonies that were selected for further culturing at 37 °C, 250 rpm for 12 h. The plasmid DNAwas then extracted and sequencing was performed with a universal primer.
